Mauro Schechter
Overview
Explore the profile of Mauro Schechter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
11042
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Apea V, Titanji B, Dakin F, Hayes R, Smuk M, Kawu H, et al.
PLOS Glob Public Health
. 2025 Feb;
5(2):e0003704.
PMID: 39951482
In May 2022, the most widespread outbreak of sustained transmission of mpox outside of countries historically affected countries in Western and Central Africa occurred. We aimed to examine the personal...
2.
Sucupira M, Schechter M, Castelo Filho A, Ferreira F, Inocencio L, Souza D, et al.
AIDS Res Hum Retroviruses
. 2024 Oct;
41(1):60-65.
PMID: 39466053
HIV RNA plasma viral load (VL) is the standard surrogate marker to monitor response to antiretroviral treatment (ART). We compared the linearity, repeatability, and concordance of six commercially available HIV...
3.
Alagaratnam J, Stohr W, Hamlyn E, Porter K, Toombs J, Heslegrave A, et al.
J Virus Erad
. 2024 Jul;
10(2):100381.
PMID: 38988673
Objective: Antiretroviral therapy (ART)-conferred suppression of HIV replication limits neuronal injury and inflammation. ART interruption tests efficacy in HIV cure trials and viral rebound after ART interruption may induce neuronal...
4.
Pena N, Santana L, Hunter J, Blum V, Vergara T, Gouvea C, et al.
BMC Infect Dis
. 2024 Jun;
24(1):612.
PMID: 38902613
Background: Predictors of the outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remain to be fully determined. We evaluated selected viral characteristics and immunological responses that might predict...
5.
Lloyd Jr R, Hunter J, Diaz R, Schechter M
Braz J Infect Dis
. 2023 Oct;
27(5):102808.
PMID: 37802129
No abstract available.
6.
Diaz R, Hunter J, Camargo M, Dias D, Galinskas J, Nassar I, et al.
BMC Infect Dis
. 2023 May;
23(1):347.
PMID: 37226112
Background: Since January 2017, the recommended first-line antiretroviral regimen in Brazil is the fixed-dose combination of tenofovir plus lamivudine with dolutegravir (TL + D). According to the literature, integrase resistance-associated...
7.
Lundgren J, Babiker A, Sharma S, Grund B, Phillips A, Matthews G, et al.
NEJM Evid
. 2023 May;
2(3).
PMID: 37213438
Background: For people with HIV and CD4 counts >500 cells/mm, early initiation of antiretroviral therapy (ART) reduces serious AIDS and serious non-AIDS (SNA) risk compared with deferral of treatment until...
8.
de Carvalho Lima E, Barros Martins G, Diaz R, Schechter M, Piqueira J, Justo J
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297440
Melanoma is an aggressive skin cancer that affects approximately 140,000 people worldwide each year, with a high fatality rate. Available treatment modalities show limited efficacy in more severe cases. Hence,...
9.
Erlandson K, Fitch K, McCallum S, Ribaudo H, Overton E, Zanni M, et al.
Clin Infect Dis
. 2022 Feb;
75(7):1154-1163.
PMID: 35165682
Background: We sought to explore multinational differences in functional status by global burden of disease (GBD) regions in the REPRIEVE cohort. Methods: REPRIEVE is a prospective, double-blind, randomized, placebo-controlled, multicenter,...
10.
Lederman M, Flier J, Hale P, Haase A, Powderly W, Reiss P, et al.
Pathog Immun
. 2022 Jan;
6(2):149-152.
PMID: 35097250
On September 10, 2021, a special tribunal established by the French government launched an inquiry into the activities of former health minister Dr. Agnes Buzyn who was charged with "endangering...